Johnson & Johnson (NYSE:JNJ) Shares Bought by Sand Hill Global Advisors LLC

Sand Hill Global Advisors LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 0.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 58,702 shares of the company’s stock after acquiring an additional 405 shares during the quarter. Sand Hill Global Advisors LLC’s holdings in Johnson & Johnson were worth $9,201,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Tower View Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares during the period. Keener Financial Planning LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $40,000. WFA Asset Management Corp lifted its holdings in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares during the period. Disciplined Equity Management Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $45,000. Finally, Altshuler Shaham Ltd increased its stake in shares of Johnson & Johnson by 37.8% in the 3rd quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock valued at $49,000 after purchasing an additional 87 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent analyst reports. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, May 6th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Finally, Bank of America cut their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $175.86.

Get Our Latest Report on JNJ

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $1.21 on Friday, hitting $148.49. 1,519,876 shares of the company were exchanged, compared to its average volume of 7,301,688. The stock has a market capitalization of $357.37 billion, a price-to-earnings ratio of 9.26, a price-to-earnings-growth ratio of 2.55 and a beta of 0.55. The company has a 50-day moving average price of $151.53 and a 200 day moving average price of $155.07. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.68 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be issued a $1.24 dividend. The ex-dividend date is Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.34%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.